erlotinib versus standard chemotherapy as first-line treatment for european patients with advanced egfr mutation-positive non-small-cell lung cancer (eurtac) a multicentre, open-label, rando..
本文档由 qingrencrh 分享于2015-10-19 09:28
erlotinib versus standard chemotherapy as first-line treatment for european patients with advanced egfr mutation-positive non-small-cell lung cancer (eurtac) a multicentre, open-label, randomised phase 3 trial
君,已阅读到文档的结尾了呢~~